- Full data from Equillium's (NASDAQ:EQ) phase 1b/2 trial of itolizumab as a potential first-line treatment for acute graft-versus-host disease (aGVHD) provided further evidence that the mAb provided a complete response in a majority of patients in 15 days.
- Also, there was a clinically meaningful reduction in corticosteroid use in these patients.
- Strong response in higher dose level groups (0.8 and 1.6 mg/kg) was observed with an overall response rate (ORR) of 100% (n=6) at day 29.
- Itolizumab was well tolerated across all doses.
- Results, presented at the Annual Meeting for the European Society for Blood and Marrow Transplantation, mirrored interim results released last month.
- Shares of Equillium are up 8.7% to $8.60 premarket.